Related Experiment Video

Updated: Aug 14, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Monoclonal antibody therapy

Deirdre O'Mahony1, Michael R Bishop

  • 1Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Frontiers in Bioscience : a Journal and Virtual Library
|December 22, 2005
PubMed

Insights

Monoclonal antibody therapy, a targeted cancer treatment, leverages immune responses and direct cell signaling for efficacy. Approved by the FDA, these therapies are significantly impacting various cancers.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Cancer pathogenesis understanding led to targeted therapy concepts.
  • Monoclonal antibodies (mAbs) activate host defense mechanisms like antibody-dependent cytotoxicity and complement-mediated cytotoxicity.

Purpose of the Study:

  • To review and discuss US Food and Drug Administration (FDA)-approved monoclonal antibodies for cancer management.
  • To explore the mechanisms of action and therapeutic potential of mAbs in oncology.

Main Methods:

  • Review of FDA-approved monoclonal antibodies for cancer treatment.
  • Discussion of the biological pathways targeted by mAbs.
  • Analysis of therapeutic efficacy, including single-agent and combination therapies.

Main Results:

  • Monoclonal antibody therapy demonstrates efficacy through multiple pathways beyond immune activation, including apoptotic signaling and growth inhibition.
  • Conjugation with radionuclides or toxins offers additional therapeutic strategies.
  • Initial data shows efficacy for single-agent use, with combination therapy showing potential for greater benefit.

Conclusions:

  • Monoclonal antibody therapy is significantly impacting the management of both solid and hematological malignancies.
  • Understanding of cancer biology is crucial for developing effective targeted antibody therapies.
  • FDA-approved mAbs represent a vital class of drugs in modern cancer treatment.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Generation of Murine Monoclonal Antibodies by Hybridoma Technology09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...